<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Foot Ankle Res</journal-id><journal-title-group><journal-title>Journal of Foot and Ankle Research</journal-title></journal-title-group><issn pub-type="epub">1757-1146</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3102978</article-id><article-id pub-id-type="publisher-id">1757-1146-4-S1-O54</article-id><article-id pub-id-type="doi">10.1186/1757-1146-4-S1-O54</article-id><article-categories><subj-group subj-group-type="heading"><subject>Oral Presentation</subject></subj-group></article-categories><title-group><article-title>Intra-articular hyaluronan (Synvisc&#x000ae;, hylan G-F 20) for the treatment of first metatarsophalangeal joint osteoarthritis: a randomised, placebo controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Zammit</surname><given-names>Gerard V </given-names></name><xref ref-type="aff" rid="I1">1</xref><email>g.zammit@latrobe.edu.au</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Munteanu</surname><given-names>Shannon E</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Menz</surname><given-names>Hylton B</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Landorf</surname><given-names>Karl B </given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Handley</surname><given-names>Christopher J</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>ElZarka</surname><given-names>Ayman</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>DeLuca</surname><given-names>Jason</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib></contrib-group><aff id="I1"><label>1</label>Musculoskeletal Research Centre, Faculty of Health Sciences, La Trobe University, Bundoora 3086, Victoria, Australia</aff><aff id="I2"><label>2</label>Department of Podiatry, Faculty of Health Sciences, La Trobe University, Bundoora 3086, Victoria, Australia</aff><aff id="I3"><label>3</label>School of Human Biosciences, Faculty of Health Sciences, La Trobe University, Bundoora 3086, Victoria, Australia</aff><aff id="I4"><label>4</label>Southern Cross Medical Imaging, La Trobe University Private Hospital, Bundoora 3083, Victoria, Australia</aff><pub-date pub-type="collection"><year>2011</year></pub-date><pub-date pub-type="epub"><day>20</day><month>5</month><year>2011</year></pub-date><volume>4</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">Proceedings of the Australasian Podiatry Council Conference 2011</named-content><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/content/pdf/1757-1146-4-S1-info.pdf">http://www.biomedcentral.com/content/pdf/1757-1146-4-S1-info.pdf</ext-link></supplement><fpage>O54</fpage><lpage>O54</lpage><permissions><copyright-statement>Copyright &#x000a9;2011 Zammit et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2011</copyright-year><copyright-holder>Zammit et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.jfootankleres.com/content/4/S1/O54"/><conference><conf-date>26-29 April 2011</conf-date><conf-name>Australasian Podiatry Council Conference 2011</conf-name><conf-loc>Melbourne, Australia</conf-loc></conference></article-meta></front><body><sec><title>Background</title><p>The objective of this randomised controlled trial (RCT) was to comparatively assess the effectiveness of intra-articular hyaluronan (Synvisc&#x000ae;, hylan G-F 20) against an intra-articular sterile saline placebo for the treatment of radiographically confirmed, symptomatic first metatarsophalangeal joint (MTPJ) osteoarthritis (OA).</p></sec><sec sec-type="methods"><title>Methods</title><p>One hundred and fifty one (n=151) participants with symptomatic first MTPJ OA were randomly allocated to receive up to 1ml intra-articular injection of either Synvisc&#x000ae;, hylan G-F 20 or a sterile saline placebo. Outcomes were evaluated at 1, 3 and 6 months post-injection. Primary outcome measurements included the <italic>foot pain</italic> and <italic>foot function</italic> sub-scales of the Foot Health Status Questionnaire (FHSQ). Secondary outcome measurements were pain at the first MTPJ during walking and rest, self-reported stiffness at the first MTPJ, magnitude of symptom change with allocated treatment, global satisfaction, health-related quality of life (assessed via the Short-Form-36, version two), first MTPJ dorsiflexion range of motion, strength of the hallux plantarflexors, use of pain-relieving medication, concomitant therapies and dynamic plantar pressures.</p></sec><sec><title>Results</title><p>This RCT was completed in July 2010, with 147 (97%) participants followed up at 1 month, 127 (84%) at 3 months and 135 (89%) at 6 months. Both the placebo and treatment groups displayed improvements at the 1, 3, and 6 month follow-up periods. However, there were no statistically significant differences between the placebo or treatment groups for the primary outcome measures of FHSQ <italic>foot pain</italic> and <italic>foot</italic><italic>function</italic> during any review period. With few exceptions, there were no statistically significant differences in the secondary outcome measurements between the groups.</p></sec><sec><title>Conclusions</title><p>A single intra-articular injection of Synvisc&#x000ae;, hylan G-F 20 is no more effective than a single intra-articular injection of sterile saline (placebo) in reducing symptoms and improving function in people with symptomatic, radiographically confirmed first MTPJ OA.</p></sec></body></article>